A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 377 participants.

Also called NCT02271217

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 377 participants (enrolled count) (from the registry)
Sponsor
Acorda Therapeutics (from the registry)
Registry
  • NCT NCT02271217
Other papers using this trial's data
  • A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke Restorative neurology and neuroscience, 2020 DOI, PubMed 32651338, PMC7592666 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02271217. Randomized; quadruple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-09 (actual). Results posted on 2017-12-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
Acronym
MILESTONE℠
Condition
Post-Ischemic Stroke
Intervention (Drug)
Placebo
Intervention (Drug)
dalfampridine-ER 7.5mg
Intervention (Drug)
dalfampridine-ER 10mg
Lead sponsor
Acorda Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02271217
Content hash
7d0989282b82b13ef31bcf531b5f35ce69aca176d053b1ce9a6a0ddd09a7c814